Table 1 Clinical characteristics of patients and distribution across treatment groups
Total of patients (n = 48) | Nivolumab + Ipilimumab (n = 12) | Pazopanib (n = 12) | Sunitinib (n = 12) | Cabozantinib (n = 12) | p-value | |
|---|---|---|---|---|---|---|
Age at diagnosis, median (range) | 70.5 (46–83) | 64 (51–83) | 76.5 (50–83) | 64 (48–77) | 73 (46–76) | – |
Gender | 0.03 | |||||
Male | 36 (75%) | 8 (66.7%) | 6 (50%) | 12 (100%) | 10 (83.3%) | |
Female | 12 (25%) | 4 (33.3%) | 6 (50%) | – | 2 (16.7%) | |
ECOG | 0.08 | |||||
0 | 28 (58.3%) | 6 (50%) | 7 (58.3%) | 3 (25%) | 2 (16.7%) | |
1 | 18 (37.5%) | 6 (50%) | 5 (41.7%) | 9 (75%) | 8 (66.7%) | |
2 | 2 (4.17%) | – | – | – | 2 (16.7%) | |
Stage at diagnosis | 0.36 | |||||
I | 5 (10.4%) | 3 (25%) | – | 4 (33.3%) | – | |
II | 6 (12.5%) | 2 (16.7%) | 2 (16.7%) | 1 (8.3%) | 1 (8.3%) | |
III | 7 (14.6%) | 2 (16.7%) | 2 (16.7%) | 2 (16.7%) | 2 (16.7%) | |
IV | 30 (62.5%) | 5 (41.7%) | 8 (66.7%) | 5 (41.7%) | 9 (75%) | |
Nephrectomy | 0.025 | |||||
Yes | 29 (60.4%) | 6 (50%) | 11 (91.7%) | 8 (66.7%) | 4 (33.3%) | |
No | 19 (39.6%) | 6 (50%) | 1 (8.3%) | 4 (33.3%) | 8 (66.7%) | |
Radiotherapy | 0.36 | |||||
Yes | 7 (14.6%) | 2 (16.7%) | 3 (25%) | 2 (16.7%) | – | |
No | 41 (85.4%) | 10 (83.3%) | 9 (75%) | 10 (83.3%) | 12 (100%) | |
Metastatic sites | 0.99 | |||||
Lung | 28 (58.3%) | 8 (66.7%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | |
Lymph Nodes | 23 (47.9%) | 6 (50%) | 6 (50%) | 5 (41.7%) | 6 (50%) | |
Bones | 18 (37.5%) | 5 (41.7%) | 3 (25%) | 5 (41.7%) | 4 (33.3%) | |
Peritoneus | 8 (16.6%) | 2 (16.7%) | 1 (8.3%) | 4 (33.3%) | 1 (8.3%) | |
Liver | 5 (10.4%) | 2 (16.7%) | 1 (8.3%) | – | 2 (16.7%) | |
CNS | 4 (8.3%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3%) | |
Adrenal | 6 (12.5%) | 2 (16.7%) | – | 3 (25%) | 1 (8.3%) | |
Other | 19 (39.5%) | 3 (25%) | 4 (33.3%) | 7 (58.3%) | 5 (41.7%) | |